Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype

Journal of Neuropathology and Experimental Neurology

Volumn 57, Issue 5, 1998, Pages 415-425

  Montine, Kathleen S ^a,c   Reich, Erin ^a   Neely, M Diana ^a   Sidell, Kathrin R ^a   Olson, Sandra J ^a   Markesbery, William R ^b   Montine, Thomas J ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; APOLIPOPROTEIN E;

AGED; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; ENTORHINAL CORTEX; FEMALE; HIPPOCAMPUS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MALE; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; TEMPORAL CORTEX;

EID: 0031836724     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199805000-00005     Document Type: Article

References (60)

1. Herbert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer's disease in a community population. J Am Med Assoc 1995;273:1354-59
2. Lilienfield DE. An epidemiological overview of amyotrophic lateral sclerosis, Parkinson's disease, and Dementia of the Alzheimer type. In: D. Calne, ed. Neurodegenerative diseases. Philadelphia: WB Saunders Co; 1994:399-426
3. Roses AD. Apolipoprotein E is a relevant susceptibility gene that affects the rate of expression of Alzheimer's disease. Neurobiol Aging 1994;15:S165-67
4. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's disease. Proc Natl Acad Sci 1995;92:4725-27
5. Bellosta S, Nathan B, Orth M, et al. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J Biol Chem 1995; 270:27063-71
6. Fagan A, Bu G, Sun Y, et al. Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. J Biol Chem 1996;271:30121-25
7. Gutman CR, Strittmatter WJ, Weisgraber KH, Matthew WD. Apo-lipoprotein E binds and potentiates the biological activity of ciliary neurotrophic factor. J Neurosci 1997;17:6114-21
8. Holtzman D, Pitas R, Kilbridge J, et al. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in central nervous system-derived neuronal cell line. Proc Natl Acad Sci USA 1995;92:9480-84
9. Huang D, Weisgraber K, Strittmatter W, Matthew W. Interaction of apolipoprotein E with laminin increases neuronal adhesion and alters neurite morphology. Exp Neurol 1995;136:251-57
10. Nathan B, Bellosta S, Sanan D, et al. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 1994; 264:850-52
11. Nathan B, Chang K, Bellosta S, et al. The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J Biol Chem 1995;270:19791-99
12. Montine TJ, Huang DY, Valentine WM, et al. Crosslinking of apolipoprotein E by products of lipid peroxidation. J Neuropathol Exp Neurol 1996;55:202-10
13. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nature Genetics 1996;14:55-61
14. Strittmatter WJ, Weisgraber KH, Goedert M, et al. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol 1994;125(2):163-71
15. Wisniewski K, Dambska M, Sher JH, Qazi Q. A clinical neuropathological study of the fetal alcohol syndrome. Neuropediatrics 1983;14:197-201
16. Subbarao KV, Richardson JS, Ang LC. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 1990;55:342-45
17. Smith CD, Carney JM, Starke-Reed PE, et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer disease. Proc Natl Acad Sci 1991;88:10540-43
18. Peterson C, Goldman JE. Alterations in calcium content and biochemical processes in cultured skin fibroblasts from aged and Alzheimer donors. Proc Natl Acad Sci 1986;83:2758-62
19. Pappolla MA, Omar RA, Kim KS, Robakis NK. Immunohistochemical evidence of antioxidant stress in Alzheimer's disease. Am J Pathol 1992;140:621-28
20. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994;36:747-51
21. Martins RN, Harper CG, Stokes GB, Masters CL. Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J Neurochem 1986;46:1042-45
22. Lovell M, Ehmann W, Butler S, Markesbery W. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 1995;45:1594-1601
23. Hensley K, Hall N, Subramaniam R, et al. Brain regional correspondence between Alzheimer's disease and histopathology and biomarkers of protein oxidation. J Neurochem 1995;65:2146-56
24. Gotz ME, Freyberger A, Hauer E, et al. Susceptibility of brains from patients with Alzheimer's disease to oxygen-stimulated lipid peroxidation and differential scanning calorimetry. Dementia 1992; 3:213-22
25. Gsell W, Conrad R, Hickethier M, et al. Decreased catalase activity but unchanged Superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem 1995;64:1216-23
26. Furuta A, Price DL, Pardo CA, et al. Localization of Superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. Am J Pathol 1995;146:357-67
27. Alpers BJ, Lewy FH. Changes in the nervous system following carbon disulfide poisoning in animals and in man. Arch Neurol Psychiat 1940;44:725-39
28. Kruman I, Bruce-Keller AJ, Bredesen D, et al. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J Neurosci 1997;17:5089-5100
29. Montine TJ, Amarnath V, Martin ME, et al. E-4-Hydroxy-2-nonenal is cytotoxic and crosslinks cytoskeletal proteins in P19 neuroglial cultures. Am J Pathol 1996;148:89-93
30. Mark RJ, Pang Z, Geddes JW, et al. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci 1997;17:1046-54
31. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic Biol Med 1991;11:81-128
32. Zollner H, Schaur RJ, Esterbauer H. Biological activities of 4-hydroxyalkenals. Oxidative Stress: Oxidants and Antioxidants 1991:337-69
33. Cohn JA, Tsai L, Friguet B, Szweda LI. Chemical characterization of a protein-4-hydroxy-2-nonenal cross link: immunochemical detection in mitochondria exposed to oxidative stress. Arch Biochem Biophys 1996;328:158-64
34. Friguet B, Stadtman ER, Szweda LI. Modification of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. J Biol Chem 1994;269:21639-43
35. Nadkarni DV, Sayre LM. Structural definition of early lysine and histidine adduction chemistry of 4-hydroxynonenal. Chem Res Toxicol 1995;8:284-91
36. Szweda LI, Uchida K, Tsai L, Stadtman ER. Inactivation of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. J Biol Chem 1992;268:3342-47
37. Uchida K, Stadtman E. Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc. Natl. Acad. Sci. USA 1992;89:4544-48
38. Uchida K, Stadtman ER. Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase. J Biol Chem 1993; 268:6388-93
39. Uchida K, Toyokuni S, Nishikawa K, et al. Michael addition-type 4-hydroxy-2-nonenal adducts in modification of low-density lipoproteins: markers for atherosclerosis. Biochemistry 1994;33:12487-94
40. Bruenner BA, Jones A, German J. Direct characterization of protein adducts of the lipid peroxidation product 4-hydroxy-2-nonenal using electrospray mass spectrometry. Chem Res Toxicol 1995;8: 552-59
41. Montine K, Olson S, Amarnath V, et al. Immunochemical detection of 4-hydroxynonenal adducts in Alzheimer's disease is associated with APOE4. Am J Pathol 1997;150:437-43
42. Sayre LM, Sha W, Xu G, et al. Immunochemical evidence supporting 2-pentylpyrrole formation on proteins exposed to 4-hydroxy-2-nonenal. Chem Res Toxicol 1996;9:1194-1201
43. Sayre LM, Arora PK, Iyer RS, Salomon RG. Pyrrole formation from 4-hydroxynonenal and primary amines. Chem Res Toxicol 1993;6:19-22
44. Graham DG, Amarnath V, Valentine WM, et al. Pathogenetic studies of hexane and carbon disulfide neurotoxicity. Crit Rev Toxicol 1995;25:91-112
45. Montine KS, Kim PJ, Olson SJ, Markesbery WR, Montine TJ. 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J Neuropathol Exp Neurol 1997;56:866-71
46. Sayre LM, Zelasko DA, Harris PLR, et al. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer disease. J Neurochem 1997;68:2092-97
47. Habeeb AF. Determination of free amino groups in proteins by trinitrobenzezesulfonic acid. Anal Biochem 1966;14:328-36
48. Kasami M, Olson S, Simpson JF, Page DL. Maintenance of polarity and a dual cell population in adenoid cystic carcinoma of the breast: An immunohistochemical study. Histochemistry 1997. Forthcoming.
49. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90(5):1977-81
50. Esiri MM, Hyman BT, Beyreuther K, Masters C. Ageing and dementia. In: Graham DI, Lantos PL, eds. Greenfield's neuropathology. London; Edward Arnold, 1996:153-234
51. Burger PC, Scheithauer BW. Tumors of the central nervous system, 3rd ed. In: Rosai J. Atlas of tumor pathology. Washington, DC: Armed Forces Institute of Pathology, 1994
52. Mark RJ, Lovell MA, Markesbery WR, et al. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J Neurochem 1997;68:255-64
53. Smith MA, Perry G, Richey PL, et al. Oxidative damage in Alzheimer's. Nature 1996;382:120-21
54. Pitas RE, Boyles JK, Lee SH, et al. Lipoproteins and their receptors in the central nervous system. J Biol Chem 1987;262:14352-60
55. Guillaume D, Bertrand P, Dea D, et al. Apolipoprotein E and lowdensity lipoprotein binding and internalization in primary cultures of rat astrocytes: isoform-specific alterations. J Neurochem 1996; 66:2410-18
56. Montine TJ, Montine KS, Swift LL. Central nervous system lipoproteins in Alzheimer's disease. Am J Pathol 1997;151:1571-75
57. Castellani R, Smith MA, Richey PL, et al. Evidence for oxidative stress in Pick disease and corticobasal degeneration. Brain Res 1995;696:268-71
58. Katzman R, Galasko D, Saitoh T, et al. Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Brain and Cognition 1995;28:259-65
59. Yoritaka A, Hattori N, Uchida K, et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci, USA 1996;93:2696-2701
60. Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging. Forthcoming.